MARKET

CLSD

CLSD

Clearside Biomed
NASDAQ
1.290
+0.040
+3.20%
Closed 17:48 04/15 EDT
OPEN
1.270
PREV CLOSE
1.250
HIGH
1.300
LOW
1.210
VOLUME
184.32K
TURNOVER
0
52 WEEK HIGH
2.120
52 WEEK LOW
0.6501
MARKET CAP
96.39M
P/E (TTM)
-2.4543
1D
5D
1M
3M
1Y
5Y
Press Release: Clearside Biomedical Appoints Seasoned Biotechnology Executive Anthony S. Gibney to its Board of Directors
Dow Jones · 18h ago
Weekly Report: what happened at CLSD last week (0408-0412)?
Weekly Report · 1d ago
Analysts Have Conflicting Sentiments on These Healthcare Companies: Abivax SA Sponsored ADR (ABVX), RxSight (RXST) and Clearside Biomedical (CLSD)
TipRanks · 5d ago
Weekly Report: what happened at CLSD last week (0401-0405)?
Weekly Report · 04/08 09:56
Clearside Biomedical to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Clearside Biomedical, Inc. Will participate in a Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference on April 10, 2024. Clearside is revolutionizing the delivery of therapies to the back of the eye through the suprachoroidal space.
Barchart · 04/02 06:05
Weekly Report: what happened at CLSD last week (0325-0329)?
Weekly Report · 04/01 09:56
12 Health Care Stocks Moving In Wednesday's After-Market Session
Avalo Therapeutics (NASDAQ:AVTX) shares moved upwards by 215.8% to $15.0 during Wednesday's after-market session. The company's Q4 earnings report came out today. Fresh2 Group stock rose upwards by 5.26% as well.
Benzinga · 03/27 20:31
Weekly Report: what happened at CLSD last week (0318-0322)?
Weekly Report · 03/25 09:57
More
About CLSD
Clearside Biomedical, Inc. is a biopharmaceutical company focused on the delivery of therapies to the back of the eye through the suprachoroidal space (SCS). The Company's SCS injection platform, utilizing its patented SCS Microinjector, enables an in-office, repeatable, non-surgical procedure for the targeted and compartmentalized delivery of a variety of therapies to the macula, retina, or choroid to potentially preserve and improve vision in patients with sight-threatening eye diseases. The Company is developing its own pipeline of small molecule product candidates for administration via its SCS Microinjector. The Company's lead program, CLS-AX (axitinib injectable suspension), for the treatment of neovascular age-related macular degeneration (wet AMD), is in Phase 2b clinical testing. It developed and gained approval for its product, XIPERE (triamcinolone acetonide injectable suspension) for suprachoroidal use, which is available in the United States through a commercial partner.

Webull offers Clearside Biomedical Inc stock information, including NASDAQ: CLSD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, CLSD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading CLSD stock methods without spending real money on the virtual paper trading platform.